MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine? We cover all that and more this

February 15, 2024

3D-printed bone: Biomimetic scaffolds offer hope for cranial defect repair

The cranial bone in the human body performs very important functions, such as protecting the brain and enabling the passage of the cranial nerves that

December 22, 2023

COVID-19 vaccines reduce infection and complications in pregnant women

The reactogenicity and impact of coronavirus disease 2019 (COVID-19) vaccines on pregnancy outcomes.

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.